Nuplazid (Pimavanserin Tartrate) Patent Expiration, LOE Window & CMS Spending
Nuplazid (Pimavanserin Tartrate) by Acadia Pharmaceuticals: FDA Orange Book core substance LOE 2030-10-29 (last listed 2037-09-23), 0 AB generics, $670.0M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Acadia Pharmaceuticals |
| FDA Application & Pathway | N207318 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2030-10-29 |
| Last Listed Patent or Exclusivity Date | 2037-09-23 |
| Orange Book Patents (*PED Extensions) | 9 patents (4 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $670.0M |
| 2024 Medicare Part D Spend | $657.8M |
| 2024 Medicaid Spend | $12.2M |
| Reported Wholesale Price Change (CA SB 17) | 2 WAC filings (max 37.3% 2-yr change) |